Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/24/2017
Start Date:May 2014
End Date:December 2018
Contact:UC Cancer Institute Clinical Trials Office
Email:kastla@ucmail.uc.edu
Phone:513-584-7698

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors

The purpose of this research study is to test the safety of chloroquine in combination with
carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid
tumors.

Also, the research study will be increasing the dose of chloroquine to find the highest dose
of chloroquine that can be given in combination with carboplatin and gemcitabine without
causing severe side effects.


Inclusion Criteria:

- Histologically confirmed diagnosis of a malignancy that is metastatic or unresectable
and for which either standard curative measures do not exist or are no longer
effective and carboplatin/gemcitabine is considered a reasonable treatment option
whether first line or acceptable and approved combination therapy.

- Age >18 years of age.

- Performance status less than or equal 2 (Karnofsky >60%)

- Life expectancy of greater than 3 months.

- Adequate labs

- Measurable disease

Exclusion Criteria:

- Current treatment with any other investigational agents.

- Patients with untreated brain metastases

- History of allergic reaction attributed to compounds of similar chemical or biologic
composition to chloroquine or other agents used in study.
We found this trial at
1
site
University of Cincinnati Cancer Institute
Cincinnati, Ohio 45267
Principal Investigator: Nagla Karim, MD, PhD
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials